510(k) device
Omnipod DASH Insulin Management System
Insulet Corporation · Pump, Infusion, Insulin (LZG, Class II) · First FDA decision Jun 1, 2018, newest Jun 1, 2018Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "Omnipod DASH"
MAUDE reports
68,715
Brand "Omnipod DASH", since 2015
PubMed studies
22
Mentioning "Omnipod DASH"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Omnipod DASH Insulin Management System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K180045 · Decided Jun 1, 2018 · 144 days after receipt
Device type: Pump, Infusion, Insulin (LZG) · Hospital Medicine & Nursing
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Insulin Infusion PumpNational analysisReview closedCAG-00041NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Omnipod DASH", any status and sponsor, newest update first.
- Outpatient Pramlintide StudyNot yet recruiting
Oregon Health and Science UniversityAcademic, hospital or other
NCT07914621 · 26 participants (planned) · Start Nov 2, 2026 · Primary completion Jan 31, 2027
Device: Single-hormone automated insulin delivery system; Dual-hormone automated insulin and pramlintide delivery system · For: Type 1 Diabetes
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Omnipod DASH", and for the whole product code for context.
This brand
68,715 reports: 62,497 malfunction, 6,139 injury, 53 death
Whole product code LZG
385,399 reports: 329,529 malfunction, 55,119 injury, 355 death
Newest reports for this brand
- Omnipod DASH Insulin Management SystemMalfunction
3014585508-2026-79836 · Received Oct 30, 2026 · Event dated Oct 1, 2026
Device type: Pump, Infusion, Insulin (LZG)
Device problem as coded: Material Twisted/Bent
Patient problem as coded: Hyperglycemia
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Omnipod DASH Insulin Management System, Product Catalog Number 18239 M/D: PDM USA1 D001 MG USA1Terminated
Z-0347-2020 · Started Dec 18, 2018
Reason given: There is a potential for a communication interruption following a bolus command that may result in inaccurate information presented in insulin on board (IOB), last bolus field or bolus history.
Cause as FDA categorized it: Software design · Device type: Pump, Infusion, Insulin (LZG)
Published research
The most relevant PubMed records for "Omnipod DASH"[tiab]. The summary above synthesizes these.
- Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial.
Kong YW, Yuan CY, Kiburg K, et al. · J Clin Endocrinol Metab · 2024Randomized Controlled Trial, Multicenter Study
- Patch Pumps: Periodic Insulin Delivery Patterns.
Eichenlaub M, Ziegler R, Heinemann L, et al. · J Diabetes Sci Technol · 2023
- Real-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes.
Forlenza GP, DeSalvo DJ, Aleppo G, et al. · Diabetes Technol Ther · 2024
- Real-world outcomes of Omnipod DASH system use in people with type 1 diabetes: Evidence from the Association of British Clinical Diabetologists (ABCD) study.
Liarakos AL, Hasan N, Crabtree TSJ, et al. · Diabetes Res Clin Pract · 2024
- Insulin Pump-Associated Adverse Events: A Qualitative Descriptive Study of Clinical Consequences and Potential Root Causes.
Estock JL, Codario RA, Keddem S, et al. · Diabetes Technol Ther · 2023Research Support, Non-U.S. Gov't
- Unintended insulin delivery using Omnipod DASH during a high-altitude flight.
Shah M, Hadian Y, Peltsverger M, et al. · BMJ Case Rep · 2022Case Reports
- Novel Bluetooth-Enabled Tubeless Insulin Pump: Innovating Pump Therapy for Patients in the Digital Age.
Ly TT, Layne JE, Huyett LM, et al. · J Diabetes Sci Technol · 2019Review
- Severe Insulin Pump-Related Adverse Events: Potential Root Causes and Impact of the COVID-19 Pandemic.
Orbell SL, Codario RA, Zupa MF, et al. · J Diabetes Sci Technol · 2025Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, P.H.S.
- Privacy Concerns Related to Data Sharing for European Diabetes Devices.
Randine P, Pocs M, Cooper JG, et al. · J Diabetes Sci Technol · 2025Research Support, Non-U.S. Gov't
- Improvements in Glycemic Outcomes in 4738 Children, Adolescents, and Adults with Type 1 Diabetes Initiating a Tubeless Insulin Management System.
Aleppo G, DeSalvo DJ, Lauand F, et al. · Diabetes Ther · 2023
- Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system.
Carlson AL, Huyett LM, Jantz J, et al. · Diabetes Res Clin Pract · 2021
- Psychosocial and Glycemic Benefits for Insulin-Using Adults With Type 2 Diabetes After Six Months of Pump Therapy: A Quasi-Experimental Approach.
Polonsky WH, Soriano EC · J Diabetes Sci Technol · 2025Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code LZG.
- Omnipod® Insulin Management System, Omnipod DASH® Insulin Management SystemInsulet Corporation · 510(k) 2021
- t:slim Insulin Delivery System, t:flex Insulin Delivery SystemTandem Diabetes Care, Inc. · 510(k) 2016
- Medtronic Minimed Paradigm Insulin PumpsMedtronic Minimed · 510(k) 2012
- Pivot Insulin Delivery SystemModular Medical, Inc. · 510(k) 2026
- Extended ReservoirMedtronic Minimed · 510(k) 2024
- Amigo Insulin PumpNipro Diabetes Systems, Inc. · 510(k) 2007
- Modular Medical MODD1 Insulin Delivery SystemModular Medical, Inc. · 510(k) 2024
- Omnipod GO Insulin Delivery DeviceInsulet Corporation · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.